Idorsia Ltd
SIX:IDIA

Watchlist Manager
Idorsia Ltd Logo
Idorsia Ltd
SIX:IDIA
Watchlist
Price: 1.154 CHF -4.15% Market Closed
Market Cap: 208m CHF
Have any thoughts about
Idorsia Ltd?
Write Note

Idorsia Ltd
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Idorsia Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Idorsia Ltd
SIX:IDIA
Research & Development
-CHf280.6m
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Research & Development
-CHf61.4m
CAGR 3-Years
-2%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Research & Development
-$320.7m
CAGR 3-Years
10%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Research & Development
-CHf77.1m
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
-4%
Kuros Biosciences AG
SIX:KURN
Research & Development
-CHf6.9m
CAGR 3-Years
-27%
CAGR 5-Years
1%
CAGR 10-Years
N/A
S
Santhera Pharmaceuticals Holding AG
SIX:SANN
Research & Development
-CHf22.7m
CAGR 3-Years
9%
CAGR 5-Years
14%
CAGR 10-Years
N/A
No Stocks Found

Idorsia Ltd
Glance View

Market Cap
217.3m CHF
Industry
Biotechnology

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

IDIA Intrinsic Value
12.593 CHF
Undervaluation 91%
Intrinsic Value
Price

See Also

What is Idorsia Ltd's Research & Development?
Research & Development
-280.6m CHF

Based on the financial report for Dec 31, 2023, Idorsia Ltd's Research & Development amounts to -280.6m CHF.

What is Idorsia Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
5%

Over the last year, the Research & Development growth was 24%. The average annual Research & Development growth rates for Idorsia Ltd have been 8% over the past three years , 5% over the past five years .

Back to Top